Signaling protein signature predicts clinical outcome of non-small-cell lung cancer

• Main Authors: Bao-Feng Jin, Fan Yang, Xiao-Min Ying, Lin Gong, Shuo-Feng Hu, Qing Zhao, Yi-Da Liao, Ke-Zhong Chen, Teng Li, Yan-Hong Tai, Yuan Cao, Xiao Li, Yan Huang, Xiao-Yan Zhan, Xuan-He Qin, Jin Wu, Shuai Chen, Sai-Sai Guo, Yu-Cheng Zhang, Jing Chen, Dan-Hua Shen, Kun-Kun Sun, Lu Chen, Wei-Hua Li, Ai-Ling Li, Na Wang, Qing Xia, Jun Wang, Tao Zhou
• Format: Article
• Language: English
• Published: BMC 2018-03-01
• Series: BMC Cancer
• Subjects: Adenocarcinoma; Non-small-cell lung cancer; Prognosis; Protein signature; Squamous cell carcinoma
• Online Access: http://link.springer.com/article/10.1186/s12885-018-4104-4

Abstract Background Non-small-cell lung cancer (NSCLC) is characterized by abnormalities of numerous signaling proteins that play pivotal roles in cancer development and progression. Many of these proteins have been reported to be correlated with clinical outcomes of NSCLC. However, none of them could provide adequate accuracy of prognosis prediction in clinical application. Methods A total of 384 resected NSCLC specimens from two hospitals in Beijing (BJ) and Chongqing (CQ) were collected. Using immunohistochemistry (IHC) staining on stored formalin-fixed paraffin-embedded (FFPE) surgical samples, we examined the expression levels of 75 critical proteins on BJ samples. Random forest algorithm (RFA) and support vector machines (SVM) computation were applied to identify protein signatures on 2/3 randomly assigned BJ samples. The identified signatures were tested on the remaining BJ samples, and were further validated with CQ independent cohort. Results A 6-protein signature for adenocarcinoma (ADC) and a 5-protein signature for squamous cell carcinoma (SCC) were identified from training sets and tested in testing sets. In independent validation with CQ cohort, patients can also be divided into high- and low-risk groups with significantly different median overall survivals by Kaplan-Meier analysis, both in ADC (31 months vs. 87 months, HR 2.81; P <  0.001) and SCC patients (27 months vs. not reached, HR 9.97; P <  0.001). Cox regression analysis showed that both signatures are independent prognostic indicators and outperformed TNM staging (ADC: adjusted HR 3.07 vs. 2.43, SCC: adjusted HR 7.84 vs. 2.24). Particularly, we found that only the ADC patients in high-risk group significantly benefited from adjuvant chemotherapy (P = 0.018). Conclusions Both ADC and SCC protein signatures could effectively stratify the prognosis of NSCLC patients, and may support patient selection for adjuvant chemotherapy.